Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Shridar Ganesan

Rutgers, the State Univ of n.j., Department: Biomedical Engineering

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Ibris Inc

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Equity Interest: Dr. Ganesan holds equity interest in, is co-founder of and consultant for a start-up company (IBRIS Inc) that is developing technology for quick and economical analysis of tissue from breast cancer biopsies, to predict how aggressive a common form of breast cancer is likely to be. The company does not have any value at this time. IBRIS Inc also holds patents on methods for image analysis of histology of ER+ breast cancers for prognosis. These patents do not have any IP value at this time. Since one of the patents contains language that includes analysis of tissue microarrays and the current study will use tissue microarrays to assess expression patterns in various types of tissue, the ICOI Committee concluded that there was the perception of a conflict of interest on the part of Dr. Ganesan.

Listed Research Project
RARE EARTH NANOPROBES FOR OPTICAL IMAGING AND DISEASE TRACKING

This project is concerned with the design and development of a new family of contrast agents based on rare earth derived nanomaterials, which will exhibit high short-wave- infrared (SWIR) emissions in different spectral ranges. The goal of this project is to administer the biologically targeted forms of these probes to detect and track small metastatic lesions during disease development and following therapeutic treatment. The overall health care applications are in diagnostic and multifunctional imaging of cardiovascular lesions/plaques, cancers, neurodegeneration, and infectious diseases.

Filed on April 21, 2016.

Tell us what you know about Shridar Ganesan's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest IBRIS Inc. $0 - $4,999
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest Ibris Inc Value cannot be readily determined
Shridar Ganesan Case Western Reserve University Conflict of Interest Inspirata, Inc. Value cannot be readily determined
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest Inspirata Inc $40,000 - $59,999
Shridar Ganesan Rbhs Cancer Institute of New Jersey Conflict of Interest Rutgers, The State University of New Jersey Value cannot be readily determined
Shridar Ganesan Rutgers, the State Univ of n.j. Conflict of Interest Rutgers, The State University of New Jersey Value cannot be readily determined
Shridar Ganesan Case Western Reserve University Conflict of Interest Inspirata, Inc. $60,000 - $79,999
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page